Skip to content Skip to navigation

Welcome

Printer-friendly versionPrinter-friendly versionPDF versionPDF version

Announcement from the COVID-19 Clinical Research Review Panel

Researchers considering any COVID-19 clinical research, including studies that require Institutional Review Board (IRB) approval as well as quality improvement projects, are required to complete a short survey at COVID-19 Clinical Research Review. For more information, click here.

Research in Response to COVID-19

  • The Research Compliance Office (IRB, SCRO, APLAC) is operating with a full staff and conducting protocol review business as usual. Incoming questions, help tickets or other support services are also being maintained.  

    In an effort to eliminate apparent immediate hazards to subjects (45 CFR 46.108(3)(iii)) and the Stanford community, all in-person visits for non-essential human research activities must be postponed, while preserving critical activity on interventional treatment trials or critical clinical research.  In light of this urgency around COVID-19, Stanford’s IRB is not requiring prior review of some protocol changes, e.g., implementing video/phone visits, mailing of study medications, or other changes designed to protect participant safety.  Understanding that resources must be prioritized, please track these changes and file a modification in eProtocol when your schedule allows.   The IRB is available to assist you with these modifications.

    ADDITIONAL COVID RESOURCES

  • Survey Results (2019-2020 Panel Year Q3 Results)
  • What's New
Quick links for researchers

Getting started

Consent Templates, Forms, eProtocol attachments

FAQs

Basics | Training | Protocol Management | Single IRB | Genomic Data Sharing | Cadavers or Deceased Individuals | Certificate of Confidentiality | GDPR | Other/Special Circumstances